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Abstract
Background: Vascular endothelial growth factor (VEGF) is thought to play an important role in the pathogenesis of
diabetic retinopathy (DR). Previous studies have associated the VEGF rs2146323 polymorphism with the risk of DR.
However, the results of these studies are inconsistent. A meta-analysis was performed to evaluate the association
between the VEGF rs2146323 polymorphism and the risk of DR.
Methods: The PubMed, EMBASE, Web of Science and Google Scholar literature databases until March 2015 were
searched. The differences in the studies were expressed in the form of an odds ratio (OR) and the corresponding 95 %
confidence interval (CI). Heterogeneity among the studies was tested using the I2 statistic based on the Q test.
Results: A total of four studies (598 cases and 709 controls) were included in the meta-analysis. A significant association
was found involving the rs2146323 polymorphism in the dominant model (CA + AA VS. CC) (OR = 1.38, CI = 1.10–1.72,
P = 0.005) and the co-dominant model (CA VS. CC) (OR = 1.37, CI = 1.08–1.74, P = 0.008).
Conclusions: Our meta-analysis confirmed the association between the VEGF rs2146323 polymorphism and the
risk of DR.
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Background
Diabetic retinopathy (DR) is considered one of the most
common microvascular complications in diabetes. It
leads to blindness among adults aged 20–74 years and is
regarded as the main cause of blindness in people with
diabetes [1]. Although the mechanisms of DR remain
largely unknown, increasing evidence has implicated
both genetics and environmental factors in the patho-
genesis of DR [2, 3].
VEGF is expressed and secreted from vascular endo-
thelial cells [4], Müller cells [5], astrocytes [6], retinal
pigment epithelial cells (RPE) [7], and ganglion cells [8];
it exerts its physiological effects by mediating vascular
permeability, angiogenesis, endothelial cell growth, cell
migration, and apoptosis [9]. Increased levels of VEGF
in the blood and the retina are linked to the patho-
genesis of DR [10]. Moreover, Anti-VEGF therapy is
currently recommended for patients with diabetic
macular edema, a very specific subtype of DR [11].
The human VEGF gene is located on chromosome
6p21.3 with 7 introns and 8 exons and shows poly-
morphism [12]. Many VEGF SNPs have been reported
showing association with DR, such as rs699947 [13],
rs833061 [14], rs3025039 [15], which have been assessed
quantitatively by meta-analyses [16–18]. But we noted
that rs2146323 have been reported showing inconsistent
association with DR [19–24]. Therefore, we conducted
this meta-analysis.
A meta-analysis is a statistical procedure of pooling
the data from individual studies, increasing the effective
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sample size, and producing a single estimate of an effect
[25]. The aim of our study was to evaluate the associ-
ation between the VEGF rs2146323 polymorphism and
DR by performing a meta-analysis.
Methods
Literature search and inclusion criteria
All the literature in PubMed, EMBASE, Web of
Science, Google Scholar literature databases was
searched. The search included only English language
publications before the deadline of the March 1st,
2015. To search all of the literature related to the
rs2146323 polymorphism, we used the following
search strategies: (vascular endothelial growth factor
or VEGF or VEGFA or “vascular endothelial growth
factor A/genetics”[mesh]) and (diabetic retinopathy or
diabetes retinopathy or DR or “diabetic retinopathy/
genetics’[mesh] or “macular edema/genetics”[mesh]).
We chose the literature that involved the polymorph-
ism based on the title and abstract of the articles and
even the full text when necessary. The meta-analysis
was performed for cases with any form of DR
compared with diabetic without retinopathy (DWR).
After removal of the duplicates, we used the following
inclusion criteria to filter the articles: (1) the study
was a case–control study; (2) definitive methods were
applied to the diagnosis of diabetic retinopathy,
including the Early Treatment of Diabetic Retinopathy
Study (ETDRS) and the guidelines of the Expert Com-
mittee Report of the American Diabetes Association
(DR includes proliferative diabetic retinopathy (PDR)
and non-proliferative diabetic retinopathy (NPDR));
(3) the VEGF rs2146323 polymorphism was evaluated;
(4) the sample size was sufficient for the calculation of
the odds ratio (OR) with 95 % confidence interval (CI);
and (5) the control group followed Hardy-Weinberg
equilibrium (HWE; a χ2 value of Pearson’s chi-square
test > 3.84 (df = 1) indicates deviation from HWE).
The most recent article will be used to extract data if
the authors published more than one article with the
same study data.
Data extraction and quality assessment
The data were independently extracted by two reviewers
and both of the reviewers’ results were submitted to a
third reviewer who verified the results. If there were
inconsistencies, the three reviewers discussed the dis-
agreements to resolve the differences. The following
items were extracted: (1) the name of the first author;
(2) the year of publication; (3) the origin country; (4) the
racial descent of the study population; (5) the sample
size of the cases and controls; (6) duration of diabetes;
(7) gender ration (male, %); (8) HbA1c level; (9) the
genotype frequency; (10) the genotyping methods; and
(11) the HWE (for the studies in which there was no
HWE assessment, we calculated this parameter) [26].
The Newcastle–Ottawa Scale (NOS) tools, which
were recommended by Cochrane, were used to evalu-
ate the quality of the eligible studies, like a previous
study [27].
Statistical analysis
The six genetics models were used for analyses: domin-
ant model: CA + AA vs. CC; allele model: A vs. C; reces-
sive model: AA vs. CA + CC; co-dominant model: CA vs.
CC; co-dominant model means AA vs. CC; over-
dominant model means CA vs. CC + AA; additive model:
CC vs. AA [25]. The differences in the studies were
expressed in the form of the odds ratio (OR) and the
corresponding 95 % confidence interval (CI). The pooled
OR was evaluated in 6 genetic models. The pooled OR
was determined using a Z test (PZ < 0.05 was considered
statistically significant). Heterogeneity among studies
was tested by the I2 statistic based on Q test. Studies
with I2 < 50 % or P > 0.10 were considered to be of low
heterogeneity, and the fixed effects model was used to
calculated the pooled OR, otherwise, random effects
model was used to pool OR. STATA software (version
12.0; STATA Corporation, College Station, TX, USA)
was used for the analyses. Two-sided P < 0.05 was
considered statistically significant.
Results
Characteristics of the studies
A total of 2724 articles were retrieved in the initial
search. Of these, 207 articles were written in a non-
English language, 2479 articles were irrelevant regarding
the VEGF polymorphism in DR, and 32 articles were
irrelevant regarding the VEGF rs2146323 polymorphism
were excluded based on reading the titles or abstracts.
In addition, 2 articles were excluded because one was
not a case–control study [24] and one was a study
previously reported by same author concerning the
same population [23]. The flow chart describing the
inclusion and exclusion of the studies is shown in
Fig. 1, and the characteristics of the included studies
are listed in Table 1. The characteristics and the qual-
ity assessment of eligible studies are listed in Table 1.
Generally, the quality of included studies was moder-
ate. The major design deficiencies of eligible studies
were as follows: 1) the authors did not report
whether the subjects were consecutively enrolled; 2)
confounding factors were not well controlled; and 3)
non-response rates were not reported.
Pooled effects analyses
A total of 598 diabetes with retinopathy (DR) cases and
709 diabetes without retinopathy (DWR) controls were
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identified (Table 2), and 6 genetic models were per-
formed for analyzing the association between the
rs2146323 polymorphism and DR. Our results showed a
significant association between the rs2146323 poly-
morphism and DR in the dominant model (CA + AA VS
CC) (OR = 1.38, CI = 1.10–1.72, PZ = 0.005, PH = 0.741)
(Fig. 2) and in the co-dominant model (CA VS CC)
(OR = 1.37, CI = 1.08–1.74, PZ = 0.008, PH = 0.529)
(Fig. 3). No significant heterogeneity was found between
the two models. In the genetic models with significant as-
sociation, the Caucasian subgroups were consistent
with the overall patient population (dominant model, OR
= 1.37, CI = 1.03–1.81, PZ = 0.031, PH = 0.538; co-domin-
ant model, OR = 1.52, CI = 1.13–2.04, PZ = 0.006, PH =
0.601). However, no significant association was found
in the Chinese subgroup (dominant model, OR =
1.40, PZ = 0.070; co-dominant model CA VS CC, OR
= 1.15, PZ = 0.470) (Table 2).
Fig. 1 Flow chart of the inclusion and exclusion of the studies
Table 1 Characteristics and quality assessment of the included studies









Yang XF [22] 2014 Asian China 490 Type 2 15 ± 5 / 13 ± 7 0.45 / 0.39 7.8 ± 1.7 / 7.0 ± 1.4 PCR-RFLP 5
Kangas-Kontio T [21] 2009 Caucasian Finland 224 Type 1/2 24 ± 10 / 25 ± 7 0.60 / 0.51 Not reported RT-PCR/Taqman 6
Abhary S [19] 2009 Caucasian Australia 487 Type 1 31 ± 13 / 15 ± 9 0.39 / 0.48 8.8 ± 2.3 / 7.6 ± 2.5 Mass spectrometer 5
Type 2 18 ± 9 / 13 ± 9 0.56 / 0.65 7.5 ± 3.4 / 6.6 ± 2.9
Churchil AJ [20] 2008 Caucasian UK 106 Type 1/2 23 / 25 0.60 / 0.52 Not reported PCR-RFLP 5
DR diabetes with retinopathy, DWR diabetes without retinopathy, PCR RFLP PCR with restriction fragment length polymorphism, HWE Hardy-Weinberg equilibrium,
NOS The Newcastle–Ottawa Scale [23]. Values are the mean ± standard deviation, where appropriate
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Risk evaluation of publication bias and sensitive analyses
We presented a basic symmetry with disperse and
uniform points in Begg’ funnel plot. Further statistical
analysis show that there were no publication bias in
the inclusive studies (dominant model: Begg’ test P = 0.308,
Egger’s test P = 0.083; allele model: Begg’ test P = 0.308,
Egger’s test P = 0.145; recessive model: Begg’ test P = 0.734,
Egger’s test P = 0.387; co-dominant model CA VS CC:
Begg’ test P = 1.000, Egger’s test P = 0.968; co-
dominant model AA VS CC: Begg’ test P = 0.734,
Egger’s test P = 0.272; over-dominant model: Begg’ test
P = 0.734, Egger’s test P = 0.595; additive model: Begg’
test P = 0.734, Egger’s test P = 0.272). We conducted
the sensitivity analysis, and results show that the
pooled OR was close to the total pooled OR and was
within the total 95 % CI, which indicated that the
results of sensitive analyses for these studies were
reliable (Figs. 4 and 5).
Discussion
The present meta-analysis confirmed the association
between the VEGF rs2146323 polymorphism and DR.
Churchil et al. [20] first reported that the +5092 C/A
(rs2146323) polymorphism was significantly associated
with proliferative diabetic retinopathy (PDR) in a
Caucasian population with type 1 or 2 diabetes,
although the sample size for analyzing this polymorph-
ism was relatively small. However, subsequent studies
showed inconsistent results. Abhary et al. [19] investi-
gated whether the rs2146323 polymorphism was signifi-
cantly associated with blinding DR in type 1 but not in
type 2 diabetic patients. Kangas-kontio et al. [21]
reported no association between rs2146323 and DR.
Yang XF et al. [22] first reported a signification associ-
ation in Chinese type 2 diabetic patients. Considering
that the data are not sufficient, we could not exclude
the correlation between the type of diabetes and the
results. The results from Caucasian populations were
consistent with the overall results. However, because
only one study in the Chinese population and three
studies in the Caucasian population were investigated,
Table 2 Genotype frequency of VEGF rs2146323 polymorphism
Author DR/DWR DWR DR HWE (χ2)
CC CA AA CC CA AA
Yang XF [22] 214/276 112 72 30 167 93 16 0.4
Kangas-Kontio T [21] 127/97 47 61 19 40 44 13 0.03
Abhary S [19] 212/275 77 113 22 129 113 33 1.13
Churchil AJ [20] 45/61 19 26 0 26 22 13 3.64
Table 3 Pooled ORs and 95 % CIs of the association between the VEGF rs2146323 polymorphism and DR in six models
Model Contrasts Number of study Pooled method OR (95 % CI) Z Pz Heterogeneity
I2 P
Dominant CA + AA vs. CC Chinese 1 Fixed-effect 1.40 (0.97–2.00) 1.81 0.070
Caucasian 3 1.37 (1.03–1.81) 2.16 0.031 0.0 % 0.538
Overall 4 1.38 (1.10–1.72) 2.82 0.005 0.0 % 0.741
Allele A vs. C Chinese 1 Random-effect 1.52 (1.14–2.03) 2.88 0.004
Caucasian 3 1.03 (0.75–1.43) 0.19 0.847 52.1 % 0.124
Overall 4 1.16 (0.88–1.53) 1.02 0.306 59.9 % 0.058
Recessive AA vs. CA + CC Chinese 1 Random-effect 2.65 (1.40–5.00) 3.01 0.003
Caucasian 3 0.73 (0.29–1.85) 0.67 0.504 63.9 % 0.063
Overall 4 1.04 (0.43–2.53) 0.09 0.928 77.5 % 0.004
Co-dominant CA vs. CC Chinese 1 Fixed-effect 1.15 (0.78–1.71) 0.72 0.470
Caucasian 3 1.52 (1.13–2.04) 2.75 0.006 0.0 % 0.601
Overall 4 1.37 (1.08–1.74) 2.63 0.008 0.0 % 0.529
Co-dominant AA vs. CC Chinese 1 Random-effect 2.80 (1.46–5.37) 3.09 0.002
Caucasian 3 0.89 (0.35–2.24) 0.25 0.801 59.0 % 0.087
Overall 4 1.26 (0.56–2.84) 0.55 0.585 70.8 % 0.016
Over-dominant CA vs. CC + AA Chinese 1 Random-effect 1.00 (0.68–1.46) 0.01 0.991
Caucasian 3 1.55 (1.09–2.21) 2.41 0.016 29.1 % 0.244
Overall 4 1.36 (0.96–1.91) 1.74 0.081 51.2 % 0.105
Additive CC vs. AA Chinese 1 Random-effect 0.36 (0.19–0.69) 3.09 0.002
Caucasian 3 1.10 (0.46–2.66) 0.22 0.828 55.2 % 0.107
Overall 4 0.79 (0.36–1.76) 0.57 0.567 69.8 % 0.019
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further studies on this polymorphism might involve
additional data that includes the population, type of
DR, and more complicated genetic or environmental
background.
To date, the mechanism of the involvement of VEGF
in DR development remains unclear. VEGF plays a cru-
cial role in DR by increasing the vascular permeability
and neovascularization [4]. Beyond the present study,
VEGF polymorphisms are significantly associated with
the risk of DR [28–30]. The significant VEGF gene
polymorphism promotes VEGF gene expression and
increases the levels of VEGF in the serum [31] and the
vitreous of the eyes of diabetic patients [32]. However,
we could not analyze the rs2146323 and VEGF levels in
Fig. 3 Meta-analysis of the association between the VEGF rs2146323 polymorphism and diabetic retinopathy in the co-dominant model (CA vs. CC)
Fig. 2 Meta-analysis of the association between the VEGF rs2146323 polymorphism and diabetic retinopathy in the dominant model (CA + AA vs. CC)
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both blood and the vitreous of diabetic eyes because of
insufficient direct data on VEGF expression levels.
VEGF +5092 C/A is located in 111-bp 5′ of exon 3,
where it is distant from the predicted transcription
factor binding sites and is not predicted to be involved
in exon splicing alterations [20]. Thus, this makes it
more effective for unveiling the mechanism of this
polymorphism on VEGF expression and function.
There are several limitations of this meta-analysis.
First, the sample size is relatively small because only four
studies were included in the meta-analysis. Second, the
effects of the type of diabetes on the association between
the polymorphism and DR were not addressed because
the primary studies did not provide the relevant data.
Third, in an attempt to overcome the confounding re-
sults of undetectable population stratification, we limited
the case and control groups to include only Caucasian
ethnicity. We found that the Caucasian subgroups were
consistent with the overall patient population. However,
there are several uncontrolled confounding factors (age,
sex, and duration of diabetes, blood glucose level, medi-
cation use, and other complications). Fourth, the present
studies did not provide the physical and biochemical
examination results, which are useful for interpreting
the mechanism of the polymorphism in DR. Finally,
although DR cases were classified by fundus photo-
graphs or OCT, level of DR has been not presented,
which may be the source of heterogeneity.
Conclusions
In conclusion, our meta-analysis results indicated that
there was a significant association between the VEGF
rs2146323 polymorphism and the risk of DR. Since
most of these polymorphisms are in strong linkage dis-
equilibrium, genome-wide association study (GWAS)
can provide more genome-wide genetic association
with DR.
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